Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis

Cassandra E. Smith, Todd N. Eagar, Jack L. Strominger, Stephen D. Miller

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The ability of different forms of myelin peptides to induce tolerance for the treatment of preestablished murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, was evaluated. i.v. administration of myelin peptide-pulsed, ethylene carbodiimide-fixed syngeneic splenocytes, but not soluble myelin peptide monomers or oligomers, proved exceedingly effective at treating preestablished EAE, resulting in amelioration of disease progression. In addition to the lack of therapeutic efficacy of soluble peptide and peptide oligomer, administering them i.v. after the onset of clinical symptoms in many but not all peptide-induced EAE models led to a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and, often, death. By using anti-IgE antibody treatments and mice with targeted mutations of the FcγRIII α-chain or the common γ-chain of FcεRI and FcγRI/III, we demonstrate that IgE crosslinking of FcεRI appears to be necessary and sufficient for myelin peptide-induced anaphylaxis. The implications of these findings to myelin peptide/protein tolerance strategies for the treatment of multiple sclerosis are discussed.

Original languageEnglish (US)
Pages (from-to)9595-9600
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number27
DOIs
StatePublished - Jul 5 2005

Fingerprint

Encephalomyelitis
Anaphylaxis
Immunoglobulin E
Peptides
Myelin Sheath
Autoimmune Experimental Encephalomyelitis
Therapeutics
Multiple Sclerosis
Myelin Proteins
Carbodiimides
Erythema
Body Temperature
Disease Progression
Mutation

Keywords

  • Myelin
  • Tolerance

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. / Smith, Cassandra E.; Eagar, Todd N.; Strominger, Jack L.; Miller, Stephen D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 27, 05.07.2005, p. 9595-9600.

Research output: Contribution to journalArticle

@article{20e7c5a50fe741ce99df3da010d77c64,
title = "Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis",
abstract = "The ability of different forms of myelin peptides to induce tolerance for the treatment of preestablished murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, was evaluated. i.v. administration of myelin peptide-pulsed, ethylene carbodiimide-fixed syngeneic splenocytes, but not soluble myelin peptide monomers or oligomers, proved exceedingly effective at treating preestablished EAE, resulting in amelioration of disease progression. In addition to the lack of therapeutic efficacy of soluble peptide and peptide oligomer, administering them i.v. after the onset of clinical symptoms in many but not all peptide-induced EAE models led to a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and, often, death. By using anti-IgE antibody treatments and mice with targeted mutations of the FcγRIII α-chain or the common γ-chain of FcεRI and FcγRI/III, we demonstrate that IgE crosslinking of FcεRI appears to be necessary and sufficient for myelin peptide-induced anaphylaxis. The implications of these findings to myelin peptide/protein tolerance strategies for the treatment of multiple sclerosis are discussed.",
keywords = "Myelin, Tolerance",
author = "Smith, {Cassandra E.} and Eagar, {Todd N.} and Strominger, {Jack L.} and Miller, {Stephen D.}",
year = "2005",
month = "7",
day = "5",
doi = "10.1073/pnas.0504131102",
language = "English (US)",
volume = "102",
pages = "9595--9600",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "27",

}

TY - JOUR

T1 - Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis

AU - Smith, Cassandra E.

AU - Eagar, Todd N.

AU - Strominger, Jack L.

AU - Miller, Stephen D.

PY - 2005/7/5

Y1 - 2005/7/5

N2 - The ability of different forms of myelin peptides to induce tolerance for the treatment of preestablished murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, was evaluated. i.v. administration of myelin peptide-pulsed, ethylene carbodiimide-fixed syngeneic splenocytes, but not soluble myelin peptide monomers or oligomers, proved exceedingly effective at treating preestablished EAE, resulting in amelioration of disease progression. In addition to the lack of therapeutic efficacy of soluble peptide and peptide oligomer, administering them i.v. after the onset of clinical symptoms in many but not all peptide-induced EAE models led to a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and, often, death. By using anti-IgE antibody treatments and mice with targeted mutations of the FcγRIII α-chain or the common γ-chain of FcεRI and FcγRI/III, we demonstrate that IgE crosslinking of FcεRI appears to be necessary and sufficient for myelin peptide-induced anaphylaxis. The implications of these findings to myelin peptide/protein tolerance strategies for the treatment of multiple sclerosis are discussed.

AB - The ability of different forms of myelin peptides to induce tolerance for the treatment of preestablished murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, was evaluated. i.v. administration of myelin peptide-pulsed, ethylene carbodiimide-fixed syngeneic splenocytes, but not soluble myelin peptide monomers or oligomers, proved exceedingly effective at treating preestablished EAE, resulting in amelioration of disease progression. In addition to the lack of therapeutic efficacy of soluble peptide and peptide oligomer, administering them i.v. after the onset of clinical symptoms in many but not all peptide-induced EAE models led to a rapid-onset anaphylactic reaction characterized by respiratory distress, erythema, decreased body temperature, unresponsiveness, and, often, death. By using anti-IgE antibody treatments and mice with targeted mutations of the FcγRIII α-chain or the common γ-chain of FcεRI and FcγRI/III, we demonstrate that IgE crosslinking of FcεRI appears to be necessary and sufficient for myelin peptide-induced anaphylaxis. The implications of these findings to myelin peptide/protein tolerance strategies for the treatment of multiple sclerosis are discussed.

KW - Myelin

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=22144479728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144479728&partnerID=8YFLogxK

U2 - 10.1073/pnas.0504131102

DO - 10.1073/pnas.0504131102

M3 - Article

C2 - 15983366

AN - SCOPUS:22144479728

VL - 102

SP - 9595

EP - 9600

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 27

ER -